Marinus Pharmaceuticals (MRNS) Stock Forecast, Price & News

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Marinus Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" MRNS shares.
View MRNS analyst ratings or view top-rated stocks.

9 Wall Street research analysts have issued twelve-month price objectives for Marinus Pharmaceuticals' stock. Their MRNS share price forecasts range from $9.00 to $32.00. On average, they expect the company's stock price to reach $21.50 in the next twelve months. This suggests a possible upside of 225.8% from the stock's current price.
View analysts price targets for MRNS or view top-rated stocks among Wall Street analysts.

Marinus Pharmaceuticals' stock was trading at $3.98 at the beginning of 2023. Since then, MRNS stock has increased by 65.8% and is now trading at $6.60.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our MRNS earnings forecast.

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) issued its quarterly earnings data on Thursday, August, 10th. The biopharmaceutical company reported ($0.61) earnings per share for the quarter, topping analysts' consensus estimates of ($0.76) by $0.15. The biopharmaceutical company had revenue of $6.08 million for the quarter, compared to analysts' expectations of $5.14 million. Marinus Pharmaceuticals had a negative net margin of 113.01% and a negative trailing twelve-month return on equity of 139.10%.

ETFs with the largest weight of Marinus Pharmaceuticals (NASDAQ:MRNS) stock in their portfolio include Simplify Propel Opportunities ETF (SURI) and iShares Neuroscience and Healthcare ETF (IBRN).Invesco Dorsey Wright Healthcare Momentum ETF (PTH).

Shares of Marinus Pharmaceuticals reverse split before market open on Wednesday, September 23rd 2020. The 1-4 reverse split was announced on Tuesday, September 22nd 2020. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, September 22nd 2020. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Marinus Pharmaceuticals investors own include Nordic American Tankers (NAT), The Gabelli Dividend & Income Trust (GDV), Sorrento Therapeutics (SRNE), Amarin (AMRN), Capricor Therapeutics (CAPR), Geron (GERN), Realty Income (O), Advanced Micro Devices (AMD), Novavax (NVAX) and Inovio Pharmaceuticals (INO).

Marinus Pharmaceuticals trades on the NASDAQ under the ticker symbol "MRNS."

Marinus Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Suvretta Capital Management LLC (8.02%), BlackRock Inc. (7.71%), Jennison Associates LLC (3.69%), Point72 Asset Management L.P. (2.62%), Franklin Resources Inc. (2.61%) and Geode Capital Management LLC (1.87%). Insiders that own company stock include Christina Shafer, Martha E Manning, Scott Braunstein, Seth H Z Fischer and Steven Pfanstiel.
View institutional ownership trends.

Shares of MRNS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MRNS stock can currently be purchased for approximately $6.60.

Marinus Pharmaceuticals (NASDAQ:MRNS) has a market capitalization of $334.03 million and generates $25.48 million in revenue each year. The biopharmaceutical company earns $-19,820,000.00 in net income (profit) each year or ($0.15) on an earnings per share basis.

The company employs 151 workers across the globe.

Marinus Pharmaceuticals' mailing address is 100 Matsonford Rd Suite 500, Radnor PA, 19087. The official website for the company is www.marinuspharma.com. The biopharmaceutical company can be reached via phone at (484) 801-4670, via email at lcaperelli@marinuspharma.com, or via fax at 203-315-0565.